Mice were treated with IL-2 in combination with agonistic antibodies to CD40, a combination that was previously demonstrated to result in marked synergistic anti-tumor effects (21, 31, 32), to determine how the thymus was effected during and after administration (Figure 1A). The gene discussed is CD40; the disease is neoplasm.